Print

NovaDigm Therapeutics to Present Positive Clinical and Preclinical Data for NDV-3 Vaccine at ICAAC  
9/12/2011 10:20:04 AM

GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL. NDV-3 is a prophylactic vaccine being developed for Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA). NDV-3 is the first vaccine to demonstrate preclinical “cross-kingdom” protective efficacy against both fungal and bacterial pathogens. NovaDigm will present Phase 1 safety and immunogenicity data for the vaccine, as well as preclinical data in a model of vulvovaginal candidiasis (VVC).
//-->